Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2009
January 2, 2009
- 2008 - The Year in Drugs
- MedWatch - Innohep (tinzaparin sodium) Dear Healthcare Professional Letter Issued Re: Increased Risk of Death in Renal Impaired Elderly
- Study is Among First to Link Short Term Drug Use for Osteoporosis to Bone Death
- AMSA Applauds Pharma Ban; Continues to Call for Federal Regulation
January 5, 2009
- Daiichi Sankyo Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories
- PPD Enters Into Strategic Collaboration with Merck
- Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
- Adventrx Announces Further Cost-Cutting Measures
January 6, 2009
- Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
- Advaxis' Phase II Clinical Trial “HOLD” Lifted
- HealthCentral Amasses Top Three Online Health Audience; Study Reveals More Consumers Turned to Internet for Health Info Than Their Physician Last Year
- CMS Reports Lowest Rate of Overall Growth in National Health Spending Since 1998
- If You Take Erectile Dysfunction Medications, Read This List
January 7, 2009
- Orion's Statutory Negotiations Completed. Personnel to be Reduced by About 205 in Finland
- Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
- Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
- Bio-Imaging Technologies Sells CapMed Division to Metavante Technologies
- Crucell and Wyeth in Discussion on a Combination of the Two Companies
January 8, 2009
- Plexxikon and Roche Enter Second Partnership to Develop PLX5568 for Polycystic Kidney Disease
- ICON plc Acquires Remaining 30% Stake in Beacon Bioscience Inc.
- Hormone Therapy Associated With Reduced Colorectal Cancer Risk
January 9, 2009
- Update of Safety Review Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
- UCB and Wilex to Enter Into Strategic Alliance to Develop UCB's Preclinical Oncology Portfolio
January 12, 2009
- FDA Awaits Court's Entry of A Permanent Injunction Against Actavis Totowa, LLC
- EpiCept Discontinues Drug Discovery Operations and Reduces Workforce
- Abbott Announces Earnings Guidance for 2009
- Pfizer Contributes Critical Data to URMC Drug Safety Initiative
January 13, 2009
- FDA Announces Two Appointments
- Elan to Review Strategic Business Alternatives
- Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound
- Merck KGaA and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
- Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth
- Update of Safety Review Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair)
January 14, 2009
- Merck Statement in Response to the FDA's Update Regarding a Safety Review of Singulair (montelukast)
- Almost Three-Quarters (70%) of Online Canadians Have Visited a Healthcare Website in the Past Year
- Use of Antidepressants Associated With Improvement in Symptoms of Fibromyalgia
- Sen. Grassley Comments on FDA Tracking of Clinical Investigators’ Financial Ties
- Nycomed Strengthens its Osteoporosis Portfolio
- FDA Launches Pilot Program To Improve the Safety of Drugs and Active Drug Ingredients Produced Outside the United States
- New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy
January 15, 2009
- Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
- Bionovo Announces Cost Control Measures Taken
- Use of Atypical Antipsychotic Drugs Increases Risk of Sudden Cardiac Death in Adults
- US Department of Health and Human Services Awards Novartis $486 Million Contract to Build Manufacturing Facility for Pandemic Flu Vaccine
- Former Johnson & Johnson Executive Gives Big Voice to Small Companies
- Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation
January 16, 2009
January 20, 2009
- Abbott Opens New Pharmaceutical Research Laboratory in Singapore
- Physician Social Networkers are High Prescribers and More Likely to Engage with Pharma
- Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
- Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
- FDA Alerts Public about Danger of Skin Numbing Products
- Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
- Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars
- Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
January 21, 2009
- Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings
- Medication May Provide Some Benefit for Older Adults With Anxiety Disorder
January 22, 2009
- European Physician Tech Tools of the Trade - Wikipedia and Social Networking?
- Biovitrum (SE) - Biovitrum aims to spin-out Cambridge Biotechnology
- Akesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File for Chapter 7 Bankruptcy
- Novartis Launches Extavia, A New Therapeutic Option To Help Patients Combat Devastating Symptoms Of Multiple Sclerosis
- Enlight Biosciences Expands to Direct up to $52 Million to Transformational Enabling Technologies
January 23, 2009
- XTENT to Retain Investment Bank to Pursue Strategic Alternatives
- UCB to Divest Selected Smaller Markets to Further Focus on its Key Strategic Areas
- Report: Pfizer May Buy Wyeth for $60 Billion
- GAO: High-Risk Series: An Update
- Grassley Works to Disclose Financial Ties Between Drug Companies and Doctors
- Penwest Sets Focused Priorities for 2009; Takes Actions to Further Reduce Costs
- Lexicon Consolidates Operations to Focus Resources on Most Advanced Drug Discovery and Development Programs
- Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
January 26, 2009
- Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
- Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 Financial Guidance
- Crucell N.V. (NL) - Discussions on a Combination of Crucell and Wyeth Discontinued
- Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
- MEDIA ADVISORY: Pfizer and Wyeth to Host Live Press Conference in New York
- Administrative Law Judge Upholds HHS-OIG Exclusions Imposed Against Responsible Corporate Officers in OxyContin Case
- Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter
- Substantial Increase in Public Preference for Generic over Brand Name Drugs
- Altus Pharmaceuticals Realigns Product Development Priorities and Focuses on Long-Acting Growth Hormone Candidate ALTU-238
- KV Pharmaceutical Suspends Product Manufacturing, Shipping
January 27, 2009
- Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
- FDA Issues an Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix)
- Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb
- Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
- Manhattan Research Survey Finds That Physicians Overwhelmingly Support Commercially-Funded Continuing Medical Education
- Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan
January 28, 2009
- CV Therapeutics Statement on Unsolicited Proposal From Astellas
- Sequenom Terminates Exchange Offer to Acquire EXACT Sciences
- Roche Delighted About Pool Extension
- Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb
- Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results
- Pharmaceutical eNewsletters Launch “XTRA” Content
January 29, 2009
- Lilly Reports Fourth-Quarter and Full-Year 2008 Results
- AstraZeneca PLC - Fourth quarter and Full Year Results 2008
- Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
- Sepracor Announces Strategic Corporate Restructuring and Workforce Reduction Plan in Addition to 2009 Financial Guidance
- Med Ad News’ 20th Annual Manny Awards Will Honor Healthcare Advertising Agencies
- Actelion Pharmaceuticals Ltd (CH) - Zavesca (miglustat) receives EU approval for the treatment of progressive neurological manifestations in patients with Niemann-Pick type C disease
- Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
- Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato Loxapine) for Acute Agitation
January 30, 2009
- Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
- FDA Sends Abbott Letter Regarding Depakote ER/Depakote Continuum Care Pharmacy Formulary Flashcard
- Lilly Announces Senior Leadership Change
- Kyowa Hakko Kirin Third Quarter Results; Revision of Full Year Forecasts; Planned Change of Fiscal Year End
- Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
- Special Committee of Genentech Board of Directors Responds to Roche's Announced Intention to Commence a Tender Offer
